It is made available under a CC-BY-NC 4.0 International license .

# Natural history of a parasite-induced biliary cancer

## Thomas Crellen<sup>1,2,3\*</sup>, Francesca Vita<sup>4,5</sup>, Chiara Braconi<sup>4,6,7</sup>, Paiboon Sithithaworn<sup>8,9</sup>, and T. Déirdre Hollingsworth<sup>2</sup>

<sup>1</sup>School of Biodiversity One Health and Veterinary Medicine, Graham Kerr Building, University of Glasgow, 82 Hillhead Street, Glasgow G12 8QQ, UK; <sup>2</sup>Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford OX3 7LF, UK; <sup>3</sup>Parasites and Microbes Program, Wellcome Sanger Institute, Hinxton CB10 1RQ, UK; <sup>4</sup> School of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Garscube Estate, Switchback Road, Glasgow G61 1QH, UK; <sup>5</sup> Department of Oncology, University of Turin, Turin 10043, Italy; <sup>6</sup> Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow G12 0YN, UK; <sup>7</sup> CRUK Scotland Cancer Centre, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK; <sup>8</sup> Department of Parasitology, Faculty of Medicine, Khon Kaen University, 123 Thanon Mittraphap, Khon Kaen 40002, Thailand; <sup>9</sup>Cholangiocarcinoma Research Institute, Khon Kaen University, 123 Thanon Mittraphap, Khon Kaen 40002, Thailand

\*Corresponding author: thomas.crellen@glasgow.ac.uk

Pathogens are major drivers of cancer globally. Quantifying the relationship between infection and carcinogenesis is therefore crucial for developing preventative programs. The foodborne trematode Opisthorchis viverrini is a primary cause of biliary cancer (cholangiocarcinoma) and infects 12 million people in Southeast Asia. In tumours from patients exposed to O. viverrini we found that the earliest chromosomal amplification of driver genes occurred at 30 years old on average, two to four decades before cancer diagnosis, and disproportionately contained FGFR2, TP53 and PTEN genes. We then fitted transmission models to parasitological data from Thailand spanning 27 years (n = 11,517) finding that, for people born between 1960–1989, first exposure occurred at two years old and by 30 years individuals had been cumulatively infected with a median of 72 worms. Trematodes are long-lived and our analysis quantifies the average lifespan of O. viverrini as 13 years (90% credible interval [Crl] 6-23 years) within human hosts. Finally, we calculate the lifetime probability of diagnosis with cholangiocarcinoma as 1.2% (90% Crl 1.0-1.4%) given prior exposure to the parasite. Overall, our study demonstrates how pathogen exposure drives patterns of cancer within human populations.

51

52

55

56

57

58

59

60

61

62

66

67

73

Keywords: Cholangiocarcinoma | Foodborne trematodiases | Cancer genomics | Somatic evolution | Epidemiology | Neglected tropical diseases

### Introduction

2

3

5

8

Infectious organisms are a major contributor to the burden 2 of human cancers globally (1), thus challenging the classic distinction between 'communicable' and 'non-communicable' diseases. Of the eleven pathogens recognised as direct human carcinogens; three are parasitic trematodes<sup>\*†</sup>. Infection with the foodborne liver flukes *Opisthorchis viverrini* and *Clonorchis* sinensis cause cancer of the bile duct (cholangiocarcinoma), 8 whilst the waterborne blood fluke Schistosoma haematobium 9 causes cancer of the bladder (squamous cell carcinoma). The 10 aetiologies resulting from infection with these parasites are 11 classified as neglected tropical diseases, owing to the historical 12 neglect of research into both the causative agents and the 13 afflicted populations (2). The pathology arising from infection 14 with parasitic worms (also known as helminths) is typically 15 chronic making it difficult to quantify the impact of any single 16 helminth species over decades of exposure and in populations 17 18 with multiple co-infections (3, 4).

19 The liver fluke *O. viverrini* has a foodborne transmission route and is acquired from eating raw or lightly fermented 20 freshwater fish, which is a traditional component of the diet in 21 regions of Southeast Asia (5). The fluke has a complex lifecycle, 22 which involves asexual reproduction within freshwater snails 23 and encysts as a mammalian-infective stage (metacercariae) 24 in cyprinid fish. Despite public health programs to control the 25 parasite, an estimated 12.4 million people were infected with 26 O. viverrini across Thailand, Laos, Cambodia and Vietnam in 27 2018 (6). While the prevalence has shown gradual declines in 28 Thailand due to periodic parasite control programs during the 29 second half of the twentieth century (7), progress has recently 30 slowed (8, 9). In Cambodia and Laos, by contrast, there is 31 evidence for increased transmission over the past two decades 32 (6, 10, 11). Liver fluke endemic countries have the highest 33 incidence of cholangiocarcinoma globally and cases of hepatic 34 and biliary cancers in these regions are disproportionately at-35 tributable to cholangiocarcinoma, rather than hepatocellular 36

carcinoma (12, 13). If an early diagnosis is made then curative 37 surgical resection is possible in a minority of cases (14). Pa-38 tients generally present late, however, and prognosis is poor 39 with a median survival time of <1 year following diagnosis and 40 the standard of care; systemic chemotherapy with cisplatin 41 plus gemcitabine (15, 16). The mechanisms through which 42 43 flukes induce cholangiocarcinoma is a combination of mechanical damage, inflammation of the biliary epithelium, and the 44 secretion of proteins; in particular the peptide granulin (17). 45

Given the poor prognosis for cholangiocarcinoma and the 46 preventable nature of parasite infection, there is a strong moti-47 vation to understand the link between liver fluke exposure and 48 carcinogensis in humans (3, 18). Prior to the onset of driver 49 mutations, anthelmintic treatment and reducing parasite ex-50 posure should be prioritised as public health interventions, whereas following the onset of irreversible malignancies the priority for interventions shifts to ultrasound screening for liver 53 pathology and early referral for surgery (19). 54

Quantifying the epidemiological relationship between liver fluke infection and the resulting biliary pathology is challenging, however, due to i) the dynamic nature of parasite transmission; ii) exposure being cumulative over time, as humans do not generate protective immunity to reinfection; iii) the long lifespan of adult worms within the human host, which is unknown for O. *viverrini*; and iv) the decades-long temporal lag between initial parasite infection and cases of cholangiocarcinoma (3, 20).

In this study we infer the timing of the earliest driver 63 64 mutations for fluke-induced cholangiocarcinoma using compu-65 tational methods which characterise the evolution of tumours from a single biopsy (21, 22). We then define the age of first exposure to liver fluke by fitting dynamic transmission models to parasitological survey data spanning several decades. Finally, 68 we estimate the lifetime probability of diagnosis with cholan-69 giocarcinoma given infection with O. viverrini. By combining 70 evolutionary cancer genomics with epidemiological analysis, we 71 obtain unique insights into the relationship between pathogen 72 exposure and tumourigenesis, with implications for evidencebased disease control (18). 74

<sup>\*</sup> https://monographs.iarc.fr/wp-content/uploads/2018/06/mono61.pdf

<sup>&</sup>lt;sup>†</sup> https://monographs.iarc.fr/wp-content/uploads/2018/06/mono100B.pdf

It is made available under a CC-BY-NC 4.0 International license .

167

181

#### Results 75

Cholangiocarcinoma tumour genomes. We obtained paired 76 tumour and normal whole-genome sequences from cholangio-77 carcinoma patients who were previously infected with liver 78 fluke and were treated at a large public hospital in North-79 80 east Thailand (23). We used a bioinformatics pipeline to call 81 somatic single nucleotide variants (SNVs), copy number alterations, and inferred the clonal status of these mutations (see 82 Methods). The age of the patients at surgery ranged from 37– 83 79 years (median 57 years), 50% of patients were female, and 84 all were born prior to 1980 (23). After mapping reads, variant 85 calling, and filtering (see Methods) we obtained 2,349-27,821 86 (median 10,360) somatic SNVs and 268-14,230 (median 1,382) 87 somatic indels per-tumour. The overall ploidy (chromosomal 88 copies) per tumour ranged from 1.2–3.7 (median 2.0). 89

Evolution of cholangiocarcinoma tumours. We estimated the 90 timing of driver mutations in 43 genes implicated in cholan-91 giocarcinoma development (24–26) using evolutionary models 92 which time the emergence of somatic single nucleotide variants 93 (SNVs) occurring on amplified sections of chromosome (21, 22). 94 We first assessed whether any tumours had been subject to 95 whole-genome duplication events based on the correlated tim-96 ings of chromosomal amplifications across the genome (21) and 97 concluded that this had occurred in three tumours (see Fig. 98 1A). Across all tumours, the copy number was disproportion-99 ately higher in chromosomes 7 and 17. In 17/22 tumours with 100 sufficient ploidy and tumour purity, we inferred the timing of 101 focal chromosomal amplifications in potential driver genes for 102 cholangiocarcinoma (see Methods). Overall the majority of 103 amplifications (166/287; 58%) occurred later in 'chronological 104 time' (0.75 or later), with a smaller proportion (46/287; 16%)105 occurring earlier in the lifespan of the tumour (before 0.5), as 106 shown in Fig. 1B. 107

Timing of amplified driver mutations. We determined the earli-108 109 est amplified driver gene for each tumour sample, and classified these as either 'clonal' (occurring on the most recent common 110 cell lineage of the tumour) or 'subclonal' (a subsequent clonal 111 expansion within the tumour which has not risen to fixation) 112 (27, 28). To calculate the age at which these amplifications 113 occurred in patients, we multiplied the chronological time es-114 115 timate with the age at surgery (see Methods). The earliest 116 clonal amplification of driver genes occurred at a median age of 30 years and with an interquartile range (IQR) of 20–43 117 years (Fig. 1C). The earliest subclonal amplifications occurred 118 at a median age of 33 years (IQR 29-41 years). A variety 119 of genes were the earliest amplified, with the most frequently 120 occurring being the tumour suppressor PTEN in the clonal 121 lineages (earliest in two tumours and amplified in 7/17 tu-122 mours), while the signalling gene NRAS was the most common 123 in subclonal lineages (earliest in two tumours and amplified in 124 7/17 tumours) see Fig. 1B. 125

To determine whether certain genes are disproportionately 126 likely to be amplified early or late within the lifespan of the 127 tumour, we applied a generalised linear model (see Methods) 128 to the chronological age estimates for each of the amplifica-129 tion events, while controlling for host sex, tumour anatomical 130 subtype (extrahepatic or perihilar) and clonality (clonal or 131 subclonal). We excluded nine amplifications with fewer than 132 eight somatic SNVs, giving 278 amplification events from 17 133 tumours for our analysis. The model estimates per gene are 134 shown by chronological age in Fig. 1D. Overall, the driver 135

genes which were disproportionately found to be amplified early 136 were the fibroblast growth factor receptor FGFR2, PTEN and 137 the tumour suppressor TP53 (these genes were amplified in 138 139 7 tumours), while the tumour suppressor genes BAP1 and PBRM1 (both amplified in 5 tumours), and the receptor gene 140 FGFR1 (amplified in 4 tumours) were preferentially amplified 141 late. Our findings add support to previous studies which have 142 noted the early clonal amplification of TP53, in particular, as 143 a driver across a range of cancer types (21). 144

Liver fluke transmission. As fluke-induced pathology of the bil-145 iary tract is chronic, there is a need to consider prior exposure 146 to the parasite at the individual or population level which can 147 be estimated from historical parasitological surveys (3). We 148 therefore collated epidemiological surveys from Northeast Thai-149 land where diagnostic observations of O. viverrini infection 150 intensity (worm burdens or faecal egg counts) were available 151 by host age. Our analysis uses data from 4,056 individuals 152 obtained from seven surveys conducted between 1980-1989, 153 prior to the onset of large-scale control programs against liver 154 fluke, and 7,448 individuals from five surveys conducted be-155 tween 1994–2017, which are summarised in Table 1. We fitted 156 a mechanistic parasite transmission model to these data which 157 considers that the parasite burden at a given age is a result 158 of flukes infecting the host with an age-variable transmission 159 rate, referred to as the 'force of infection', and parasites exit 160 the host due the spontaneous death rate of adult worms (20). 161 Full model details are provided in Methods. 162

Exposure to liver fluke in human populations. The average age 163 at which a person born between 1960–1989 was first infected 164 with a single O. viverrini fluke is 22 months (90% prediction 165 interval [PI] 19–25 months). The average age of first infection 166 for a person born after 1990 rises to 8 years (90% PI 6.5–9.5years), though a smaller proportion of the population ultimately 168 becomes exposed during their lifetime; 33% post-intervention 169 compared with 88% pre-intervention. We define exposure to O. 170 *viverrini* as the cumulative number of adult flukes acquired by 171 a person over time, which is given by the area under the force of 172 173 infection curve (Equation 6). In endemic regions of Thailand in 174 the 1980s by ages 10, 20, and 30 years the median number of O. viverrini flukes acquired was 12 (90% PI 8-16), 39 (90% PI 27-175 53), and 72 (90% PI 48–103) respectively (Fig. 2C). Following 176 public health interventions in the 1990s (7), we estimate that 177 the O. viverrini force of infection dropped substantially, with 178 an almost 40-fold reduction in the age-dependent transmission 179 180 rate, resulting in the majority of individuals born after 1990 remaining uninfected by age 30 (median worm burden is zero). 182 The distribution of *O. viverrini* parasites among human hosts shows high variation, as is characteristic for helminths (29). 183 184 and for the top decile of the most heavily infected hosts the cumulative burden is >693 worms by 30 years of age in the 185 pre-intervention period (90% PI 523-931) and  $\geq$ 14 worms in 186 the post-intervention period (90% PI 10-21). These findings 187 add weight to the reported declines in parasite transmission in 188 Thailand following control programs (6-8), though our analysis 189 is the first to quantify this effect in terms of worm burden, the 190 age of first exposure, and the cumulative proportion exposed. 191

Lifespan of the adult worm. The lifespan of helminths in hu-192 man infections is considered to be in the order of one year 193 to three decades, although this is rarely quantified (30, 31). 194 We estimate the lifespan of O. viverrini within our force of 195 infection model as 12.9 years (90% CrI 6.2–23.1 years), which 196





**Fig. 1.** Evolution of cholangiocarcinoma tumours. A) Subclonal lineage reconstruction for cholangiocarcinoma tumour CCA\_TH19 using MutationTimeR (21). The upper plot shows the variant allele frequency (VAF) for somatic SNVs which are coloured by clonal state; clonal (early) = green, clonal (late) = purple, clonal (unknown) = blue, subclonal = red. The middle plot shows the inferred copy number frequency (ploidy) by chromosome. The lower plot shows the inferred timings of copy number gains. For this tumour, the timings of copy number gains are correlated across chromosomes, indicating a whole-genome duplication event at a 'mutation time' of 0.6. B) Histogram showing the timing of 287 clonal and subclonal amplification events for 44 driver mutations in 17 cholangiocarcinoma tumours inferred by AmplificationTimeR (22). C) The earliest amplified clonal and subclonal driver mutations in cholangiocarcinoma (CCA) tumours (22) multiplied by the patient age at surgery (23) to give the inferred age for each amplification event. Each point represents the first amplified driver gene per patient, labelled with the gene name, and the points are coloured by tumour anatomical subtype (intrahepatic or perihilar). The overlaid box and whisker plots shows the median and interquartile range. D) Estimates of the chronological time of amplification by gene. Results are shown from a generalised linear model applied to estimates from AmplificationTimeR (see Methods). The black points give the posterior median, the thick blue line gives the 50% credible interval.

is defined as the average time for half of adult stage parasites 197 to die within the human host in the absence of anthelmintic 198 treatment (Equation 3, see Methods). Our posterior distri-199 bution for parasite mortality is long tailed (Fig. 2) with the 200 top five percent of adult O. viverrini lifespans  $\geq 25.7$  years. 201 This finding is consistent with case reports of the related liver 202 fluke C. sinensis from travellers, which is known to persist in 203 human hosts for 26 years (32). We note that the posterior 204 distribution of the worm mortality parameter is correlated 205 with a force of infection parameter, and therefore we encourage 206 207 use of the interval for O. viverrini adult worm lifespan (6–23) 208 years), rather than the point estimate, in future analyses.

Latent and induction periods of cholangiocarcinoma. Bringing 209 together the evidence presented thus far, we hypothesise that 210 people born between 1960–1989 in Northeast Thailand first 211 became infected with liver fluke by age two and driver muta-212 tions for biliary cancer occurred around age 30. We sought to 213 validate our hypothesis using cancer registry data (33). The 214 age distribution of 10,737 cases of cholangiocarcinoma diag-215 nosed in Northeast Thailand between 1985–2009 are shown in 216 Figure 3A. The median age of diagnosis was 59 years between 217 1985–1997 and 63 years between 1997–2009. Using a time-to-218 219 event analysis, which accounts for interval censored data, we 220 estimated the age of driver mutation and the subsequent age of cholangiocarcinoma as sequential gamma distributions (see 221 Methods). The induction period (time from initial parasite 222

It is made available under a CC-BY-NC 4.0 International license .



**Fig. 2.** Epidemiological data on the carcinogenic liver fluke *Opisthorchis viverrini* in Thailand. A) Worm burdens of *O. viverrini* by participant age, inferred from multiple surveys conducted between 1980–1989 prior to large–scale interventions. The data used for model fitting were counts of i) adult worms obtained from autopsy, or ii) worm expulsion, or iii) parasite eggs in faeces (data shown from S1–S6, see Table 1). The fitted black line shows the simulated median worm burden by host age, with the shaded area giving the 90% prediction interval (model fitted to data from S1–S7; see Table 1). The y-axis is log transformed. B) Proportion of exposed population with at least one parasite in the pre–intervention (1980–1989; S1–S7) and post–intervention periods (1994–2017; S8–S12 see Table 1). Solid lines are central estimates and shaded areas give the 90% credible interval (CrI). Where the solid lines cross the dashed line, this gives the age at which half of the exposed population become first infected, which is 22 months (90% CrI 19–25 months) of age in the pre–intervention period and 8 years of age (90% CrI 7–9.5 years) in the post–intervention period. C) Cumulative exposure to *O. viverrini* by age (Equation 6). The solid line shows the simulated median for the pre–intervention period, while the dot–dash lines show the cumulative worm burden for the upper 90% population percentile. Shaded areas give the 90% prediction interval. The y-axis is log transformed. D) Average lifespan of adult *O. viverrini* worms in human hosts. The posterior probability density is shown here for  $log(2)/\sigma$ ; where  $\sigma$  is the spontaneous death rate of adult worms (Equation 3). Dashed line gives the posterior median (13 years). The filled area gives the 90% CrI (6–23 years).

infection to driver mutation) was estimated as 28 years (90%) 223 CrI 16–39 years) and the latent period (time from driver mu-224 tation to cancer diagnosis) was estimated as 32 years (90%225 CrI 21–44 years). These distributions are shown in Fig. 3B. 226 The incidence data therefore supports our estimate of the time 227 to first amplified mutation at thirty years, given exposure 228 by age two. The latent period estimate from registry data 229 is longer than the 22 years indicated by our earlier analysis 230 of the tumour genomes (time between first amplified driver 231 mutation and biliary surgery), which likely reflects an older 232 average age of diagnosis in the registry data compared to our, 233 much smaller, sample of patients with sequenced biliary tu-234 mours (23, 33). Prior research on the induction and latent 235

periods for fluke-induced cholangiocarcinoma in humans has 236 been limited, though American veterans from the Vietnam 237 238 War had an elevated incidence of biliary cancer five or more decades after potential exposure to O. viverrini between 1965-239 1971 (34). While the association between military service in 240 Vietnam and fluke-induced cholangiocarcinoma is contentious 241 (35), the reported time between parasite exposure and cancer 242 for United States veterans (induction plus latent period) is 243 consistent with our findings. 244

Lifetime probability of cholangiocarcinoma. We estimate the
 lifetime probability of acquiring cholangiocarcinoma by fitting
 a survival model (see Methods) to age-incidence cancer registry

It is made available under a CC-BY-NC 4.0 International license .



**Fig. 3.** Incidence of cholangiocarcinoma (CCA) at the population level. A) The age distribution of 10,737 cases of cholangiocarcinoma from Northeast Thailand between 1985–2009 (33). B) Time-to-event distributions for the induction period (from parasite exposure to driver mutation) and the latent period (from driver mutation to cancer diagnosis). The plots show the posterior probability distributions, where the dashed line gives the median and the shaded orange area shows the 90% credible interval (Crl). The induction period was estimated as a median of 28 years and the latent period as 32 years. C) Annual incidence of cholangiocarcinoma per 100,000 people by age for Northeast (N.E.) Thailand, where the carcinogenic liver fluke *O. viverrini* is endemic, and Malaysia which is non-endemic for *O. viverrini*. D) Cumulative lifetime probability of diagnosis with cholangiocarcinoma for the two populations, N.E. Thailand and Malaysia, at age *a*, conditional on survival to age *a*. The model output is shown from a survival analysis (Equation 17, see Methods), where the solid black lines give the posterior median and the shaded areas the 90% Crl. Probability given as a percentage (%).

data from Northeast Thailand between 1998–2009 (33) and 248 Malaysia between 2007–2009 (36), which neighbours Thailand 249 but is non-endemic for liver fluke (37). The underlying data are 250 shown in Fig. 3C as an annual population incidence per 100,000 251 population and the survival model predictions are shown in Fig. 252 3D. Our results show that by 75 years of age the cumulative 253 probability of diagnosis with cholangiocarcinoma, conditional 254 on the person surviving to that age, is 0.046% in Malaysia 255 (90% CrI 0.039-0.054%) and 0.99% in Northeast Thailand 256 (90% CrI 0.85–1.1%), which is twenty-fold higher. Under the 257 assumptions that 90% of excess cancer cases in Northeast 258 Thailand are attributable to infection with liver fluke (38) and 259 the total proportion of the population exposed to the parasite 260 between 1960–1989 was 88% (estimated above, see Fig. 2B.), 261 we calculate the probability of developing cholangiocarcinoma, 262

given prior infection with O. viverrini, as 1.0% (90% CrI 0.87-263 1.2%) by 75 years of age and 1.2% (90% CrI 1.0–1.4%) by 264 265 85 years. While a previous report suggested a higher lifetime probability of 5% (39), the data and method used to produce 266 this estimate are unclear. Calculating the lifetime probability 267 of cancer given infection depends on the population exposed 268 to O. viverrini. Prevalence surveys taken at a single moment 269 in time will underestimate this proportion (38, 40), and hence 270 overestimate the relative probability of cancer among infected 271 people. The probability of developing cholangiocarcinoma 272 covaries with the infection intensity of liver fluke (41). Given 273 improved longitudinal data, the lifetime probability of biliary 274 cancer should be stratified by the cumulative worm burden in 275 future analyses. 276

It is made available under a CC-BY-NC 4.0 International license .

341

351

352

353

354

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

391

394

396

397

399

#### Discussion 277

Our study uncovers many crucial, yet previously unknown, epi-278 demiological processes on the pathway from parasite infection 279 to carcinogenesis in humans. The aim of such research is to 280 inform control programs to reduce both transmission of liver 281 282 fluke and subsequent cases of cancer (18, 19). Given the find-283 ings presented here, that the age of first fluke infection is prior to ten years of age and the first amplified driver mutations for 284 biliary cancer are on average at 30 years of age, we recommend 285 that interventions should be targeted to younger individuals 286 in at-risk regions, such as school-based deworming with the 287 anthelmintic praziquantel (42). Relatively few studies have 288 investigated the impact of anthelmintic treatment on prevent-289 ing or reversing biliary damage in humans (43-45), though the 290 current evidence suggests a beneficial effect of deworming even 291 in the context of repeated reinfection. The long temporal lag 292 of four to seven decades between first parasite exposure and 293 diagnosis with cholangiocarcinoma (see Fig. 2B and Fig. 3) 294 means that changes to O. viverrini transmission intensity will 295 take many years to influence the incidence of cholangiocarci-296 noma at the population level (19). Future randomised clinical 297 trials investigating the impact of deworming with praziquantel 298 on the risk of biliary cancer could be considered unethical 299 given the need to withhold or restrict anthelmintic treatment 300 for controls (18). Dynamic simulations have a useful role to 301 play, therefore, in estimating the magnitude of interventions 302 over long time periods (46). Our results provide a platform 303 for biomarker discovery by highlighting early driver genes and 304 we argue that screening for biliary malignancies should start 305 from thirty years of age. Furthermore, the long latent period 306 provides a window for early the rapeutic interventions (47). 307

While there are relatively few studies investigating the epi-308 demiological relationship between infection and carcinogenesis, 309 when compared against other pathogen-driven cancers our 310 estimates of the induction and latent periods for fluke-induced 311 cholangiocarcinoma appear to be longer. For human papillo-312 mavirus (HPV), the time from infection to high-grade cervical 313 intrapithelial neoplasia (CIN2/3) has been estimated from reg-314 istry data as three years, and the time from CIN2/3 to cancer 315 23.5 years (48). The time from infection with hepatitis B to 316 hepatocellular carcinoma is reported as 25-30 years in a review 317 (49), though we are unaware of any supporting evidence. Mech-318 anisms for a potentially longer tumorigenesis from O. viverrini 319 infection, compared with other carcinogenic pathogens, have 320 not been investigated. We note that the impact of fluke in-321 fection on biliary pathology is dose-dependent (41), and so 322 depends on the distribution of parasites within an endemic 323 community (40). There may also be evolutionary reasons for a 324 slower accumulation of pathology from helminths, given their 325 long lifespans (30, 50). 326

As the data used here are primarily from Northeast Thailand 327 our estimates of epidemiological parameters are most applicable 328 to this region. Large-scale ultrasound screening programs for 329 liver disease in Thailand have successfully diagnosed thousands 330 of cholangiocarcinoma and pre-cancerous cases since 2015 (51). 331 However, the enhanced screening will likely lead to short-term 332 increases in the reported incidence of cholangiocarcinoma, thus 333 further complicating our understanding of the relationship 334 between parasite infection and cancer (19). Extending our 335 336 analyses to Laos and Cambodia, where the burden of parasitic 337 disease is greater (6, 10) and the capacity for healthcare systems to diagnose and treat biliary cancer more limited (52), remains 338 a priority for future research. 339

#### **Methods and Materials** 340

Cholangiocarcinoma whole-genome sequences. We accessed paired tumour-normal whole-genome sequences from 22 in-342 dividuals in Northeast Thailand with previous exposure to 343 344 liver fluke infection. Tumour tissue was obtained from patients 345 during surgical resection of the biliary tract at Srinagarind Hos-346 pital in Khon Kaen, Thailand (23). Normal somatic genomes were obtained from patient blood samples. Tumours are classi-347 fied according to their anatomical location on the biliary tree; 348 namely intrahepatic cholangiocarcinoma (within the hepatic 349 ducts), perihilar cholangiocarcinoma (between second order 350 bile ducts and the cystic duct insertion) or distal cholangiocarcinoma (below the cystic duct). Here our samples consisted of eight perihilar and 14 intrahepatic tumours. The age at surgery ranged from 37-79 years (median 57 years) and 11/22355 (50%) of patients were female.

Cancer Genomics. Starting with fastq files, we trimmed adaptor sequences from 150bp illumina paired-end reads using TrimGalore v.0.4.4 (53) and mapped the reads against the human reference (GRCh37) using bwa mem v.0.7.17 with default parameters (54). The resulting BAM files were then sorted and indexed with samtools v.1.9. Duplicates were marked and removed using GATK v.4.1.4.1 (55) and base quality scores re-calibrated for tumour sequences with ICGC PCAWG consensus vcf files as known variants for single nucleotide variants (SNVs) and indels (56). Examining the depth of mapped reads, we took the output from samtools depth -a (including zeroes) and binned the mean depth within 1Mb segments (Fig. 1A). Overall we found that the mean sequencing depth averaged across the whole genomes ranged from 35x-73x per-sample (median 57x) for normal genomes and 45x-72x per-sample (median 54x) for tumour genomes.

We called somatic SNVs and indels using GATK Mutect2 with a panel of normals provided by the Broad Institute (57), and with additional filters to remove secondary and supplementary reads. Prior to filtering, the number of somatic SNVs ranged from 109,339-292,886 per sample (median 131,057). We calculated the fraction of reads in the normal with tumour contamination using the GATK tool CalculateContamination in combination with 4.7 million common germline alleles (MAF 0.01–0.20) derived from diverse Asian populations in Singapore (58). This revealed that the contamination in normal samples was low with <0.7% of reads coming from cross-sample contamination. Using the data on contamination, we filtered the Mutect2 variants calls, leaving 2,349–27,821 (median 10,360) somatic SNVs and 268-14,230 (median 1,382) somatic indels per-tumour. The number of somatic variants called in our samples are consistent with those observed for other biliary cancers (59).

Subclonal reconstruction. We estimated tumour copy number 389 using the Battenberg algorithm (27), with reference data from 390 the 1000 Genomes Project. The estimated fraction of tumour cells (rather than normal tissue) in our cholangiocarcinoma 392 genomes, also known as the tumour purity or cellularity, varied 393 substantially between samples (range 10–90%; median 60%). The overall ploidy per tumour ranged from 1.2–3.7 (median 395 2.0). We then phased somatic variants and assigned them to subclonal lineages (28) using dpclust3p and dpclust (60), implemented in R v.4.3.2. The number of clonal and subclonal 398 lineages, which variants were assigned to, varied from 2-5 per tumour (median 3). 400

457

458

459

461

462

463

464

465

467

470

Timing of driver mutations. We applied algorithms to estimate 401 the chronological timing of driver mutations in amplified re-402 gions; MutationTimeR (21) and AmplificationTimeR (22), 403 which were implemented in R v.4.3.3. The MutationTimeR 404 algorithm uses a panel of 371 known driver mutations identified 405 by the PCAWG consortium (59). We used the temporal corre-406 lation of copy number gains from MutationTimeR to identify 407 if tumours had undergone whole–genome duplication (21). For 408 the AmplificationTimeR analysis, we focused on timing the 409 amplification of 43 driver mutations which have been identi-410 fied as important in early–stage cholangiocarcinoma (25, 26)411 or previously detected in these tumours (23). The estimates 412 for the chronological time of amplifications were calibrated 413 using C>T mutations at CpG sites, which have been estab-414 lished to have clock-like properties (61). The age in years at 415 which driver gene amplifications occurred was calculated as 416 the product of the bootstrapped chronological time estimates 417 from AmplificationTimeR (22), which fall in the interval [0, 1], 418 and the patient's age at surgery (23). 419

Earliest and latest amplified genes. We used a generalised 420 linear model to determine which genes were amplified dispro-421 portionately early or late within the lifespan of the tumour. 422 We modelled the chronological time estimates for gene  $g(y_{t,q})$ , 423 estimated by AmplificationTimeR (22) with a minimum of 424 10 mutations, which fall in the interval [0,1] using a beta 425 distribution parameterised by a mean  $\mu_q$  and precision  $\kappa$ 426

$$y_{t,q} \sim Beta\_Proportion(\mu_q, \kappa),$$
 [1]

where the mean is a transformed linear function of a gene-428 specific intercept  $(\alpha_g)$  plus covariates (x) and slopes  $(\beta)$ . The 429 three binary explanatory variables are the sex of the patient, 430 whether the tumour is intrahepatic or perihilar, and whether 431 the amplification is clonal or subclonal 432

$$\mu_{g} = logit^{-1} (\alpha_{g} + \beta_{1}x_{1} + \beta_{2}x_{2} + \beta_{3}x_{3}).$$
 [2]

The model was fitted in a Bayesian framework using the 434 stan language v.2.34.1 (62) implemented with cmdstanr v.0.7.1 435 (63) in R v.4.3.3; see details on parameter estimation below. 436

Liver fluke surveys. We obtained data from epidemiological 437 surveys on the liver fluke O. viverrini in Thailand between 438 1980–2017. The parasitological observations in these surveys 439 consisted of i) adult worms obtained from liver dissection at 440 autopsy, ii) adult worms recovered through expulsion following 441 anthelminthic treatment, or iii) parasite egg counts obtained 442 by faecal examination, see Table 1. We contacted the study 443 authors to obtain parasitological data by host age. Where 444 these were unavailable, we simulated individual-level data from 445 446 summary tables which contained the sample size, mean, and variance for parasitological observations (worm burdens or 447 faecal egg counts) aggregated by age group using a Pearson 448 type I distribution. 449

Parasite transmission model. We developed a mechanistic 450 model that incorporates key aspects of parasite ecology (20, 30)451 fitted to individual-level data on adult worm burdens or faecal 452 egg counts (Table 1). Our process model characterises the 453 mean worm burden at the population level (M) by host years 454 of age (a) as an immigration-death process 455

427

$$\frac{dM}{da} = \lambda(a) - M\sigma, \qquad [3]$$

Survey & Method	Province	District	Year(s)	<b>n</b> <sup>1</sup>	Age Range
S1 Autopsy (64)	Khon Kaen	Multiple <sup>2</sup>	1982–9	159	2–78
S2 Expulsion (65)	Khon Kaen	Ban Nam	1987	33	15–56
S3 Expulsion (66)	Kalasin	Huai Mek	1989	373	5–60
S4 Faecal egg (67)	Khon Kaen	Chonnabot	1980	1651	1–72
S5 Faecal egg (68)	Multiple	Rural <sup>3</sup>	1981–3	433	1–65
S6 Faecal egg (68)	Multiple	Urban <sup>3</sup>	1981–3	126	1–70
S7 Prevalence (69)	Khon Kaen	Nong Wai	1981	1284	1–65
S8 Faecal egg (7)	Multiple	Multiple	1994	65	1–70
S9 Prevalence (7)	Multiple	Multiple	1994	1912	1–70
S10 Prevalence (70)	Ratchasima	Multiple	2010–1	1168	5–90
S11 Prevalence (71)	Multiple	Multiple	2013	3916	15–70
S12 Prevalence (72)	Khon Kaen	Khon Kaen	2016–7	387	11–91

Table 1. Cross-sectional surveys analysed in this study investigating the relationship between host age and Opisthorchis viverrini worm burden, faecal egg counts, or prevalence by faecal egg diagnostic (Fig. 2A). Surveys were conducted in Northeast (N.E.) Thailand either before the onset of liver fluke control programs (S1-S7; pre-intervention), or following a national control program in the early 1990s (S8-S12; post-intervention). Age range of the participants is shown in years. <sup>1</sup>Sample size of human participants in survey. <sup>2</sup>Autopsy cases were from N.E. Thailand, with the majority from Khon Kaen province. <sup>3</sup>Hospital-based study where patients from N.E. Thailand were recruited and classified as originating from either rural or urban communities.

where  $\sigma$  gives the spontaneous death rate of adult worms in the absence of anthelmintic treatment. The expected lifespan of adult O. viverrini parasites is therefore given as the time taken for half of adult worms to die in the absence of 460 anthelmintic treatment;  $log(2)/\sigma$ . As there is evidence for agedependent reinfection rates (73), we model the *O. viverrini* force of infection as a function of host age

$$\lambda(a) = \eta a e^{-\beta a}.$$
 [4]

The dynamic model (Equations 3 and 4) has the following 466 analytical solution for worm burden by age a,

$$M(a) = \frac{\eta e^{-a\sigma}}{(\beta - \sigma)^2} \left( 1 + e^{a(\sigma - \beta)} (a(\sigma - \beta) - 1) \right).$$
 [5]

The cumulative parasite exposure  $(\delta)$  by age *a* is given by 468 the definite integral of the force of infection (Equation 4) 469

$$\delta(a) = \int_0^a \eta a e^{-\beta a} \, da.$$
 [6]

Observation model for survey data. The true number of 471 O. viverrini adult worms per individual i of age group  $a(x_{i,a})$ 472 follows the negative binomial distribution (NB), which takes 473 the form of a gamma–Poisson mixture model parameterised 474 with a mean worm burden M(a) (Equations 3 and 5) and age-475 dependent dispersion  $k_a$  (40). Values of  $k_a$  are estimated for 476 each age-group and are themselves normally distributed with 477 an overall mean of  $\mu_k$  and a standard deviation of  $\sigma_k$ . During 478 autopsy surveys, adult O. viverrini were carefully removed 479 from cross-sections of liver and worm recovery is likely close to 480 100%, therefore we consider that the true worm count for each 481 individual is equal to the recovered worms in autopsy studies 482  $(x_{i,a} \equiv w_{i,a} \mid r = 1),$ 483

484 
$$Pr(X_{i,a} = x_{i,a} \mid M(a), k_a) =$$
  
485  $NB(x_{i,a} \mid M(a), k_a).$  [7]

[8]

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580 581

582

583

584

585

[14]

In surveys where O. viverrini flukes were obtained by expulsion, 486 participants were treated with the anthelmintic praziquantel 487 followed by a saline purgative, which is known to result in 488 imperfect subsequent recovery of from faeces (74). Therefore, 489 we allow the true worm burden to be greater than, or equal 490 to, the observed number of worms for individuals in expulsion 491 studies  $(x_{i,a} \ge w_{i,a})$  and the probability of observing  $w_i$  worms 492 given a true count of  $x_i$  is a binomial sampling process with 493 probability of worm recovery r = 0.44 (40), 494

95 
$$Pr(W_{i,a} = w_{i,a} \mid M(a), k_a, r) =$$
96 
$$\sum_{x=w_{i,a}}^{\infty} Binom(w_{i,a} \mid x, r) \cdot NB(x \mid M(a), k_a),$$

where Binom refers to a standard binomial probability distribu-497 tion. In surveys where the outcome variables are eggs per gram 498 of stool (y), if at least one egg is observed for individual i of 499 age group  $a (y_{i,a} \ge 1)$ , we relate this to the expected egg count 500 for that individual using a negative binomial error distribution, 501 where the mean is given as a density-dependent function of the 502 true worm burden;  $\pi(x) = (\Lambda x)^{\gamma}$  and the dispersion is given 503 by parameter h, which has previously been estimated for O. 504 viverrini as 0.4 (40), 505

506 
$$Pr(Y_{i,a} = y_{i,a} \mid M(a), k_a, \Lambda, \gamma, h) = \sum_{x=1}^{\infty} NB(y_{i,a} \mid \pi(x), h) \cdot NB(x \mid M(a), k_a).$$
[9]

Where zero eggs are observed  $(y_{i,a} = 0)$ , we consider the individual diagnostic sensitivity as a saturating function of the worm burden, se(x) = x/(x+b), where the parameter *b* has been previously estimated for *O. viverrini* as 1.7 (40),

512 
$$Pr(Y_{i,a} = 0 \mid M(a), k_a, b) =$$
513 
$$\sum_{i=1}^{\infty} \left(1 - \frac{x}{1-x}\right) \cdot NB(x \mid M(a), k_a).$$

$$\sum_{x=0} \left(1 - \frac{x}{x+b}\right) \cdot NB\left(x \mid M(a), k_a\right).$$
 [10]

The population level sensitivity (S) for faecal egg diagnostics is a function of the worm burden distribution at the population level (40),

517 
$$S(M,k) = \sum_{x=1}^{\infty} se(x) \cdot \binom{x+k-1}{x} \frac{\left(\frac{k}{M+k}\right)^k \left(\frac{M}{M+k}\right)^x}{p(M,k)}, \quad [11]$$

where p(M,k) indicates the true prevalence and is given by

519 
$$p(M,k) = 1 - \left(\frac{k}{M+k}\right)^k$$
. [12]

Given an assumed diagnostic specificity of one, the observed prevalence p' for for age group a is therefore related to the true prevalence with the following expression,

$$p' = p(M,k) \cdot S(M,k) + (1 - p(M,k)) \cdot (1 - sp), \quad [13]$$

where sp gives the faecal egg diagnostic specificity, which is assumed here to be 1. For surveys where only the prevalence is given by faecal egg diagnostic, we represent this as individual– level positive or negative outcomes;  $z_{i,a} \in \{0, 1\}$ . The probability for the binary diagnostic observations is therefore given by a Bernoulli distribution

530 
$$Pr(Z_{i,a} = z_{i,a} \mid M(a), k_a, b) = \begin{cases} p'_a & \text{if } z_{i,a} = 1\\ 1 - p'_a & \text{if } z_{i,a} = 0. \end{cases}$$

523

Epidemiological parameter estimation. Model fitting was per-532 formed in a Bayesian framework using the stan language 533 v.2.34.1 (62) implemented with cmdstanr v.0.7.1 (63) in R 534 535 v.4.3.3. Parameters were assigned weakly or moderately informative prior distributions based on the results from a previous 536 analysis (40) for the pre-intervention data (S1-S7, see Table 537 1). For the post-intervention analysis (S8-S12), several model 538 parameter values were taken directly from the pre-intervention 539 analysis posterior distributions; including the parameters relat-540 ing worm burdens to egg counts  $(\Lambda, \gamma)$  and the worm mortality 541 rate  $(\sigma)$ , which was taken as the highest percentile of the pos-542 terior estimate ( $\sigma = 0.116$ ), corresponding to a mean worm 543 lifespan of 6 years, to account for higher parasite mortality re-544 sulting from periodic anthelmintic treatment. Each model was 545 run with four parallel chains with a burn-in of 1700 iterations 546 per chain and a total of 1000 iterations. The Gelman-Rubin 547 548 diagnostic  $\hat{r} \leq 1.01$  and effective sample size >500 were used 549 to diagnose successful Markov chain convergence. Results are presented as credible intervals (CrI) of parameter posterior 550 distribution or prediction intervals (PI) from simulations. 551

Induction and latent period. We performed a time-to-event analysis to validate the induction and latent periods estimated by the earlier evolutionary cancer analysis using populationlevel data. We obtained the age distribution of 10,737 cases of cholangiocarcinoma diagnosed at Srinagarind Hospital between 1985–2009 (33) which were grouped into age classes. We consider that for each cancer case at age a there is an unknown age at which a driver mutation was obtained m, where m < a. Values of m are drawn from a gamma distribution with mean  $\mu_{mut}$ and shape parameter  $\alpha_{mut}$ . Following the mutation at age mthere is a latent period before cancer diagnosis at age a, this latent period is also gamma distributed with mean  $\mu_{cca}$  and shape  $\alpha_{cca}$ . The probability of developing cholangiocarcinoma at age a,  $\phi_a$  is therefore

$$\phi_a = \sum_{m=1}^{a-1} Gamma(m \mid \mu_{mut}, \alpha_{mut}) \cdot Gamma(a - m \mid \mu_{cca}, \alpha_{cca}).$$
[15]

Cholangiocarcinoma cases are reported by age group with a lower bound of l and an upper bound of u in years. The likelihood  $\mathcal{L}$  for each observation is therefore optimised on the interval probability, given by

$$\mathcal{L} = 1 - \prod_{a=l}^{u} (1 - \phi_a).$$
 [16]

**Probability of acquiring cholangiocarcinoma.** We adopt a binomial regression framework with the probability of contracting cholangiocarcinoma at age a in years given by

$$\pi_a = logit^{-1} (\alpha_a + \beta x_f), \qquad [17]$$

where  $\alpha$  is an age dependent intercept and  $\beta$  is a coefficient multiplied by a binary variable  $x_f \in \{0, 1\}$  indicating whether the cases of cholangiocarcinoma come from a region endemic for liver fluke ( $x_f = 1$  for Thailand and  $x_f = 0$  for Malaysia). Values of  $\alpha$  are drawn from a multivariate normal distribution with a covariance matrix which accounts for temporal autocorrelation between years.

Counts of cholangiocarcinoma cases c are reported by age group with a lower bound l and an upper bound of u in years

### It is made available under a CC-BY-NC 4.0 International license .

655

656

657

658 659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

and are therefore interval censored. Cases are drawn from an
underlying population of size N. We can therefore express a
binomial likelihood function for each interval,

$$Pr(C_l^u = c_l^u | N_l^u, \theta_l^u) = Binom(c_l^u | N_l^u, \theta_l^u), \quad [18]$$

where the interval probability of cancer  $\theta_l^u$  is related to the yearly probability

$$\theta_l^u = 1 - \prod_{a=l}^u (1 - \pi_a).$$
[19]

We thank Dr. Stefan Dentro and

Data on cholangiocarcinoma cases in Thailand come from 593 the cancer registry at Srinagarind Hospital in Khon Kaen (33). 594 For this analysis we used counts of cholangiocarcinoma cases 595 between 1998–2009 along with corresponding demographic 596 data (N) for Khon Kaen in the same period (75). Cancer case and demographic data for Malaysia between 2007-2009 were obtained from the World Health Organization Mortality 599 Database (36), using version 10 ICD codes C22 (malignant neo-600 plasm of liver and intrahepatic bile ducts) and C24 (malignant 601 neoplasm of other and unspecified parts of biliary tract). We 602 assumed that half of these biliary cancers were attributable to 603 cholangiocarcinoma (17) and, given the very low survival rate, 604 that mortality is a valid approximation for incidence (15, 16). 605

### 606 Acknowledgements.

589

592

Prof. Moritz Gerstung for providing additional code relating to the
PCAWG consortium analysis to calculate mutation times of 2,778
tumour genomes. We appreciate the comments from Dr. Arporn
Wangwiwatsin and Prof. Watcharin Loilome on a poster relating
to this manuscript. We further thank Dr. Jessica Clark and Dr.
Paul Johnson for discussions on the survival analysis. Dr. Claudio
Nunes-Alves also provided valuable feedback on the manuscript.

Access to whole-genome paired cancer and normal sequence data was approved by the International Cancer Genome Consortium Data Access Compliance Office (reference: DACO-63). We acknowledge the important role of Prof. Apinya Jusakul, Prof. Patrick Tan and colleagues for originally generating this sequence data.

Access to the SG10K\_Pilot data was approved by the National 619 Precision Medicine Data Access Committee in Singapore (Applica-620 tion no. SG10KP00043). We thank the 'SG10K Pilot Investigators' 621 for providing the 'SG10K Pilot data' (EGAD00001005337). The 622 data from the 'SG10K\_Pilot Study' reported here were obtained 623 from EGA. This manuscript was not prepared in collaboration with 624 the 'SG10K\_Pilot Study' and does not necessarily reflect the opin-625 626 ions or views of the 'SG10K\_Pilot Study'.

We used data from the World Health Organization (WHO) Mortality Database for biliary cancer incidence. The analyses, interpretations and conclusions shown in this article are attributable solely to the authors and not to WHO, which is responsible only for the provision of the original information.

This research was funded in whole, or in part, by the Wellcome 632 Trust [Grant number 215919/B/19/Z]. For the purpose of open ac-633 cess, the author has applied a CC BY public copyright licence to any 634 Author Accepted Manuscript version arising from this submission. 635 C.B. acknowledges that this study was performed under the 636 collaborative umbrella of the European Network for the Study 637 of Cholangiocarcinoma (EURO-CHOLANGIO-NET) supported by 638 COST action (CA) 18122 and the Precision-BTC network supported 639 by CA22125. F.V. acknowledges funding from a short term grant 640 from EURO-CHOLANGIO-NET CA18122. 641

P.S. acknowledges funding from the National Research Council
of Thailand as part of the Fluke–Free Thailand program.

Ethical Statement. As an analysis of previously published and
anonymous human data, this study met the criteria for exemption
from ethical review at the Universities of Oxford and Glasgow.

647 **Data and Code Accessibility.** This study uses previously pub-648 lished datasets. Code to reproduce the analysis is available at 649 https://github.com/tc13/ov-cca-models/.  Authors' Contributions. T.C. conceptualised the study, T.C. developed methodology, T.C. analysed epidemiological data, T.C and
 F.V. analysed cancer genomic data, P.S provided resources, C.B. provided supervision for cancer genomics, T.D.H. provided supervision
 for epidemiological modelling, T.C. wrote the manuscript.

**Competing Interests.** C.B. received honoraria as speaker (AstraZeneca, Incyte) and consultant (Incyte, Servier, Boehringer Ingelheim, AstraZeneca, Jazz Therapeutics, Tahio), received research funds (Avacta, Medannex, Servier) and her spouse is an employee of AstraZeneca. The other authors declare no competing interests.

### References

- Catherine de Martel, Damien Georges, Freddie Bray, Jacques Ferlay, and Gary M Clifford. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. The Lancet global health, 8(2):e180–e190, 2020.
- Peter J Hotez. Forgotten people, forgotten diseases: the neglected tropical diseases and their impact on global health and development. John Wiley & Sons, 2021.
- Anna Borlase, Joaquin M Prada, and Thomas Crellen. Modelling morbidity for neglected tropical diseases: the long and winding road from cumulative exposure to long-term pathology. *Philosophical Transactions of the Royal Society B*, 378(1887):20220279, 2023.
- Sergi Alonso, Moses Arinaitwe, Alon Atuhaire, Andrina Barungi Nankasi, Joaquín M Prada, Emma McIntosh, and Poppy HL Lamberton. The short-term impact of schistosoma mansoni infection on health-related quality of life: implications for current elimination policies. *Proceedings* B, 291(2024):20240449, 2024.
- Carl Grundy-Warr, Ross H Andrews, Paiboon Sithithaworn, Trevor N Petney, Banchop Sripa, Luxana Laithavewat, and Alan D Ziegler. Raw attitudes, wetland cultures, life-cycles: sociocultural dynamics relating to opisthorchis viverrini in the mekong basin. *Parasitology international*, 61(1):65–70, 2012.
- Ting-Ting Zhao, Yi-Jing Feng, Pham Ngoc Doanh, Somphou Sayasone, Virak Khieu, Choosak Nithikathkul, Men-Bao Qian, Yuan-Tao Hao, and Ying-Si Lai. Model-based spatial-temporal mapping of opisthorchiasis in endemic countries of southeast asia. *elife*, 10:e59755, 2021.
- P Jongsuksuntigul and T Imsomboon. The impact of a decade long opisthorchiasis control program in northeastern thailand. The Southeast Asian Journal of Tropical Medicine and Public Health, 28(3):551–557, 1997.
- Apiporn Suwannatrai, Prasert Saichua, and Melissa Haswell. Epidemiology of Opisthorchis viverrini infection. Advances in Parasitology, 101:41–67, 2018.
- Oranard Wattanawong, Sopon lamsirithaworn, Thongroo Kophachon, Worayuth Nak-Ai, Ampas Wisetmora, Thitima Wongsaroj, Paron Dekumyoy, Choosak Nithikathkul, Apiporn T Suwannatrai, and Banchob Sripa. Current status of helminthiases in Thailand: A cross-sectional, nationwide survey, 2019. Acta Tropica, 223:106082, 2021.
- Virak Khieu, Thomas Fürst, Kazuko Miyamoto, Tai-Soon Yong, Jong-Yil Chai, Rekol Huy, Sinuon Muth, and Peter Odermatt. Is opisthorchis viverrini emerging in cambodia? Advances in parasitology, 103:31–73, 2019.
- Bong-Kwang Jung, Sooji Hong, Taehee Chang, Jaeeun Cho, Seungwan Ryoo, Keon Hoon Lee, Jeonggyu Lee, Woon-Mok Sohn, Sung-Jong Hong, Virak Khieu, et al. High endemicity of opisthorchis viverrini infection among people in northern cambodia confirmed by adult worm expulsion. *Scientific Reports*, 13(1):9654, 2023.
- V Vatanasapt, N Martin, H Sriplung, K Chindavijak, S Sontipong, H Sriamporn, DM Parkin, and J Ferlay. Cancer incidence in thailand, 1988-1991. *Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*, 4(5):475–483, 1995.
- Andrea A Florio, Jacques Ferlay, Ariana Znaor, David Ruggieri, Christian S Alvarez, Mathieu Laversanne, Freddie Bray, Katherine A McGlynn, and Jessica L Petrick. Global incidence and trends in intra-and extrahepatic cholangiocarcinoma from 1993 to 2012. *Cancer*, 126(11):2666, 2020.
- William R Jarnagin, Yuman Fong, Ronald P DeMatteo, Mithat Gonen, Edmund C Burke, Jessica Bodniewicz, Miranda Youssef, David Klimstra, and Leslie H Blumgart. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. *Annals of surgery*, 234(4):507–519, 2001.
- Juan Valle, Harpreet Wasan, Daniel H Palmer, David Cunningham, Alan Anthoney, Anthony Maraveyas, Srinivasan Madhusudan, Tim Iveson, Sharon Hughes, Stephen P Pereira, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. New England Journal of Medicine, 362(14):1273–1281, 2010.
- Sumera Rizvi, Shahid A Khan, Christopher L Hallemeier, Robin K Kelley, and Gregory J Gores. Cholangiocarcinoma—evolving concepts and therapeutic strategies. *Nature reviews Clinical oncology*, 15(2):95–111, 2018.
- Banchob Sripa, Paul J Brindley, Jason Mulvenna, Thewarach Laha, Michael J Smout, Eimorn Mairiang, Jeffrey M Bethony, and Alex Loukas. The tumorigenic liver fluke Opisthorchis viverrini–multiple pathways to cancer. *Trends in Parasitology*, 28(10):395–407, 2012.
- Thomas Crellen, Paiboon Sithithaworn, Opal Pitaksakulrat, Narong Khuntikeo, Graham F Medley, and T Déirdre Hollingsworth. Towards evidence-based control of Opisthorchis viverrini. *Trends in Parasitology*, 37(5):370–380, 2021.
- Narong Khuntikeo, Bandit Thinkhamrop, Thomas Crellen, Chatanun Eamudomkarn, Trevor N Petney, Ross H Andrews, and Paiboon Sithithaworn. Epidemiology and control of opisthorchis viverrini infection: Implications for cholangiocarcinoma prevention. In *Liver Fluke, Opisthorchis* viverrini *Related Cholangiocarcinoma: Liver Fluke Related Cholangiocarcinoma*, pages 27–52. Springer, 2023.
- 20. GF Medley and DA Bundy. Dynamic modeling of epidemiologic patterns of schistosomiasis
- morbidity. The American journal of tropical medicine and hygiene, 55(5 Suppl):149–158, 1996.
   21. Moritz Gerstung, Clemency Jolly, Ignaty Leshchiner, Stefan C Dentro, Santiago Gonzalez, Daniel Rosebrock, Thomas J Mitchell, Yulia Rubanova, Pavana Anur, Kaixian Yu, et al. The evolutionary history of 2,658 cancers. Nature, 578(7793):122–128, 2020.

# It is made available under a CC-BY-NC 4.0 International license . 817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

- 22. G Maria Jakobsdottir, Stefan C Dentro, Robert G Bristow, and David C Wedge. Amplification-731 732 timer: An r package for timing sequential amplification events. Bioinformatics, page btae281, 733 2024
- 734 23. Apinya Jusakul, Ioana Cutcutache, Chern Han Yong, Jing Quan Lim, Mi Ni Huang, Nisha 735 Padmanabhan, Vishwa Nellore, Sarinya Kongpetch, Alvin Wei Tian Ng, Ley Moy Ng, et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarci-736 737 noma. Cancer discovery, 7(10):1116-1135, 2017.
- Benjamin Goeppert, Trine Folseraas, Stephanie Roessler, Matthias Kloor, Anna-Lena Volckmar, 738 24. Volker Endris, Ivo Buchhalter, Albrecht Stenzinger, Krzysztof Grzyb, Marit M Grimsrud, et al. 739 740 Genomic characterization of cholangiocarcinoma in primary sclerosing cholangitis reveals therapeutic opportunities. Hepatology, 72(4):1253-1266, 2020. 741
- 742 25. Benjamin Goeppert, Damian Stichel, Reka Toth, Sarah Fritzsche, Moritz Anton Loeffler, 743 Anna Melissa Schlitter, Olaf Neumann, Yassen Assenov, Monika Nadja Vogel, Arianeb Mehrabi, 744 et al. Integrative analysis reveals early and distinct genetic and epigenetic changes in intraductal 745 papillary and tubulopapillary cholangiocarcinogenesis. Gut, 71(2):391-401, 2022.
- 746 26. Khaa Hoo Ong, Yao-Yu Hsieh, Hong-Yue Lai, Ding-Ping Sun, Tzu-Ju Chen, STEvEN KuAN-747 HuA HuANG, Yu-Feng Tian, Chia-Lin Chou, Yow-Ling Shiue, Hung-Chang Wu, et al. Lamc2 is a potential prognostic biomarker for cholangiocarcinoma. Oncology Letters, 26(6):1-14, 2023. 748
- 749 27. Serena Nik-Zainal, Peter Van Loo, David C Wedge, Ludmil B Alexandrov, Christopher D 750 Greenman, King Wai Lau, Keiran Raine, David Jones, John Marshall, Manasa Ramakrishna, 751 et al. The life history of 21 breast cancers. Cell, 149(5):994-1007, 2012.
- Stefan C Dentro, David C Wedge, and Peter Van Loo. Principles of reconstructing the subclonal 752 28. 753 architecture of cancers. Cold Spring Harbor perspectives in medicine, 7(8):a026625, 2017.
- DJ Shaw, BT Grenfell, and AP Dobson. Patterns of macroparasite aggregation in wildlife host 29. 754 populations. Parasitology, 117(6):597-610, 1998. 755
  - 30. Roy M Anderson and Robert M May. Infectious diseases of humans: dynamics and control. Oxford University Press, 1991.

756

757

758

759

760

761

762

763

764

765

768

774

777

- 31. Jae Hoon Lim. Liver flukes: the malady neglected. Korean journal of radiology, 12(3):269-279, 2011.
- 32. HD Attwood and ST Chou. The longevity of Clonorchis sinensis. Pathology, 10(2):153-156, 1978.
- 33. Suppt Kamsa-ard, Surapon Wiangnon, Krittika Suwanrungruang, Supannee Promthet, Narong Khuntikeo, Siriporn Kamsa-ard, Suwannee Mahaweerawat, et al. Trends in liver cancer incidence between 1985 and 2009, khon kaen, thailand: cholangiocarcinoma. Asian Pac J Cancer Prev, 12(9):2209-2213, 2011.
- 766 34. George Psevdos, Florence M Ford, and Sung-Tae Hong. Screening US vietnam veterans for 767 liver fluke exposure 5 decades after the end of the war. Infectious Diseases in Clinical Practice. 26(4):208-210, 2018.
- Theodore E Nash, David Sullivan, Edward Mitre, Eric Garges, Victoria J Davey, Gary Roselle, 769 35. 770 Stephen J Davies, and Peter D Rumm. Comments on "Screening US Vietnam veterans for liver 771 fluke exposure 5 decades after the end of the war". Infectious Diseases in Clinical Practice, 26 772 (4):240-241, 2018.
- World Health Organization. website, February 2024. URL https://www.who.int/data/ 773 36. data-collection-tools/who-mortality-database. WHO Mortality Database
- 775 37 Banchob Sripa, Apiporn T Suwannatrai, Somphou Sayasone, Dung Trung Do, Virak Khieu, and 776 Yichao Yang. Current status of human liver fluke infections in the greater mekong subregion. Acta tropica, 224:106133, 2021.
- 778 38 D Maxwell Parkin, Petcharin Srivatanakul, Myriam Khlat, Dhiraphol Chenvidhya, Pornarong 779 Chotiwan, Somchai Insiripong, Kristan A L'abbé, and Christopher P Wild. Liver cancer in 780 thailand. i. a case-control study of cholangiocarcinoma. International journal of cancer, 48(3): 781 323-328, 1991.
- 782 39. Nopparat Songserm, Supannee Promthet, Paiboon Sithithaworn, Chamsai Pientong, Tipaya 783 Ekalaksananan, Peechanika Chopjitt, and Donald Maxwell Parkin. Risk factors for cholangiocarcinoma in high-risk area of thailand: role of lifestyle, diet and methylenetetrahydrofolate 784 reductase polymorphisms. Cancer epidemiology, 36(2):e89-e94, 2012. 785
- Thomas Crellen, Melissa Haswell, Paiboon Sithithaworn, Somphou Sayasone, Peter Odermatt, 786 40. Poppy HL Lamberton, Simon EF Spencer, and T Déirdre Hollingsworth. Diagnosis of helminths 787 788 depends on worm fecundity and the distribution of parasites within hosts. Proceedings of the Royal Society B, 290(1991):20222204, 2023. 789
- 790 41. Melissa R Haswell-Elkins, Soisungwan Satarug, Mitsuhiro Tsuda, Eimorn Mairiang, Hiroyasu 791 Esumi, Paiboon Sithithaworn, Pisain Mairiang, Minoru Saitoh, Puangrat Yongvanit, and David B Elkins. Liver fluke infection and cholangiocarcinoma: model of endogenous nitric oxide 792 793 and extragastric nitrosation in human carcinogenesis. Mutation Research/Fundamental and 794 Molecular Mechanisms of Mutagenesis, 305(2):241-252, 1994.
- 795 42. Joanne P Webster, David H Molyneux, Peter J Hotez, and Alan Fenwick. The contribution of 796 mass drug administration to global health: past, present and future. Philosophical Transactions 797 of the Royal Society B: Biological Sciences, 369(1645):20130434, 2014.
- 798 43. Eimorn Mairiang, Melissa R Haswell-Elkins, Pisaln Mairiang, Paiboon Sithithaworn, and David B 799 Elkins. Reversal of biliary tract abnormalities associated with Opisthorchis viverrini infection following praziquantel treatment. Transactions of the Royal Society of Tropical Medicine and 800 Hygiene, 87(2):194-197, 1993. 801
- 44. S Pungpak, C Viravan, B Radomyos, K Chalermrut, C Yemput, W Plooksawasdi, M Ho, 802 T Harinasuta, and D Bunnag. Opisthorchis viverrini infection in thailand: studies on the 803 morbidity of the infection and resolution following praziquantel treatment. The American journal 804 of tropical medicine and hygiene, 56(3):311-314, 1997. 805
- 45. Eimorn Mairiang, Thewarach Laha, Sasithorn Kaewkes, Alex Loukas, Jeffrey Bethony, Paul J 806 Brindley, and Banchob Sripa. Hepatobiliary morbidities detected by ultrasonography in 807 opisthorchis viverrini-infected patients before and after praziquantel treatment: a five-year 808 follow up study. Acta tropica, 217:105853, 2021. 809
- 46. Sue J Goldie, Daniel Grima, Michele Kohli, Thomas C Wright, Milton Weinstein, and Eduardo 810 Franco. A comprehensive natural history model of hpv infection and cervical cancer to estimate 811 the clinical impact of a prophylactic hpv-16/18 vaccine. International Journal of cancer, 106(6): 812 813 896-904. 2003.
- 47. Do-Youn Oh, Aiwu Ruth He, Shukui Qin, Li-Tzong Chen, Takuji Okusaka, Arndt Vogel, 814 Jin Won Kim, Thatthan Suksombooncharoen, Myung Ah Lee, Masayuki Kitano, et al. Durval-815 umab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM evidence, 1(8): 816

EVIDoa2200015, 2022.

- 48. Margaretha A Vink, Johannes A Bogaards, Folkert J van Kemenade, Hester E de Melker, Chris JLM Meijer, and Johannes Berkhof. Clinical progression of high-grade cervical intraepithelial neoplasia: estimating the time to preclinical cervical cancer from doubly censored national registry data. American journal of epidemiology, 178(7):1161-1169, 2013.
- William M Lee. Hepatitis b virus infection. New England journal of medicine, 337(24):1733-49. 1745, 1997.
- SA Frank and P Schmid-Hempel. Mechanisms of pathogenesis and the evolution of parasite 50. virulence. Journal of evolutionary biology, 21(2):396-404, 2008.
- Kavin Thinkhamrop, Narong Khuntikeo, Nittaya Chamadol, Apiporn T Suwannatrai, Surachai 51. Phimha, and Matthew Kelly. Associations between ultrasound screening findings and cholangiocarcinoma diagnosis in an at-risk population. Scientific Reports, 12(1):13513, 2022.
- 52. Phonepasong Ayé Soukhathammavong, Virasack Rajpho, Khampheng Phongluxa, Youthanavanh Vonghachack, Jan Hattendorf, Bouasy Hongvanthong, Oroth Rasaphon, Banchob Sripa, Kongsap Akkhavong, Christoph Hatz, et al. Subtle to severe hepatobiliary morbidity in opisthorchis viverrini endemic settings in southern laos. Acta tropica, 141:303-309, 2015.
- 53. Felix Krueger. URL https://github.com/FelixKrueger/TrimGalore. Github.
- Heng Li and Richard Durbin. Fast and accurate short read alignment with burrows-wheeler transform. bioinformatics, 25(14):1754-1760, 2009.
- 55. Geraldine A Van der Auwera and Brian D O'Connor. Genomics in the cloud: using Docker, GATK, and WDL in Terra. O'Reilly Media, 2020.
- PCAWG. URL https://dcc.icgc.org/releases/PCAWG/consensus\_snv\_indel. DACO. 56.
- Broad Institute. URL https://console.cloud.google.com/storage/browser/gatk-best-practices. 57. GATK Best Practices.
- Degang Wu, Jinzhuang Dou, Xiaoran Chai, Claire Bellis, Andreas Wilm, Chih Chuan Shih, 58. Wendy Wei Jia Soon, Nicolas Bertin, Clarabelle Bitong Lin, Chiea Chuen Khor, et al. Largescale whole-genome sequencing of three diverse asian populations in singapore. Cell, 179(3): 736-749, 2019.
- 59. The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature, 578(7793):82-93, 2020.
- Niccolo Bolli, Hervé Avet-Loiseau, David C Wedge, Peter Van Loo, Ludmil B Alexandrov, 60. Inigo Martincorena, Kevin J Dawson, Francesco Iorio, Serena Nik-Zainal, Graham R Bignell, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nature communications, 5(1):2997, 2014,
- Zane Koch, Adam Li, Daniel S Evans, Steven Cummings, and Trey Ideker. Somatic mutation 61. as an explanation for epigenetic aging. bioRxiv, 2023.
- 62. Bob Carpenter, Andrew Gelman, Matthew D Hoffman, Daniel Lee, Ben Goodrich, Michael Betancourt, Marcus Brubaker, Jigiang Guo, Peter Li, and Allen Biddell, Stan: A probabilistic programming language. Journal of Statistical Software, 76(1), 2017.
- 63. Jonah Gabry, Rok Češnovar, and Andrew Johnson. cmdstanr: R Interface to 'CmdStan', 2023. https://mc-stan.org/cmdstanr/, https://discourse.mc-stan.org.
- Paiboon Sithithaworn, Smarn Tesana, Vichit Pipitgool, Sasithorn Kaewkes, Kasemsri Thaik-64. lar, Chavalit Pairojkul, Bunchob Sripa, Anucha Paupairoj, Pisit Sanpitak, and Chanarong Aranyanat. Quantitative post-mortem study of Opisthorchis viverrini in man in North-East Thailand. Transactions of the Royal Society of Tropical Medicine and Hygiene, 85(6):765-768, 1991
- Roger J Ramsay, Paiboon Sithithaworn, Paul Prociv, Douglas E Moorhouse, and Chingchai 65. Methaphat. Density-dependent fecundity of Opisthorchis viverrini in humans, based on faecal recovery of flukes. Transactions of the Royal Society of Tropical Medicine and Hygiene, 83(2): 241-242 1989
- 66. MR Haswell-Elkins, DB Elkins, Paiboon Sithithaworn, Phattara Treesarawat, and Sasithorn Kaewkes. Distribution patterns of opisthorchis viverrini within a human community. Parasitology, 103(1):97-101, 1991.
- ES Upatham, V Viyanant, S Kurathong, J Rojborwonwitaya, WY Brockelman, S Ardsungnoen, 67. P Lee, and S Vajrasthira. Relationship between prevalence and intensity of opisthorchis viverrini infection, and clinical symptoms and signs in a rural community in north-east thailand. Bulletin of the World Health Organization, 62(3):451, 1984.
- 68. Sucha Kurathong, Pravit Lerdverasirikul, Virasak Wongpaitoon, Chutima Pramoolsinsap, and E Suchart Upatham. Opisthorchis viverrini infection in rural and urban communities in northeast thailand. Transactions of the Royal Society of Tropical Medicine and Hygiene, 81(3):411-414, 1987.
- S Sornmani, FP Schelp, P Vivatanasesth, W Patihatakorn, P Impand, P Sitabutra, P Worasan, 69. and S Preuksaraj. A pilot project for controlling o. viverrini infection in nong wai, northeast thailand, by applying praziquantel and other measures. Arzneimittel-forschung, 34(9B):1231-1234, 1984
- Soraya J Kaewpitoon, Ratana Rujirakul, and Natthawut Kaewpitoon. Prevalence of opisthorchis 70. viverrini infection in nakhon ratchasima province, northeast thailand. Asian Pacific Journal of Cancer Prevention, 13(10):5245-5249, 2012.
- 71. Kesorn Thaewnongiew, Seri Singthong, Saowalux Kutchamart, Sasithorn Tangsawad, Supannee Promthet, Supan Sailugkum, and Narong Wongba. Prevalence and risk factors for opisthorchis viverrini infections in upper northeast thailand. Asian Pacific Journal of Cancer Prevention, 15(16):6609-6612, 2014.
- 72. Pokkamol Laoraksawong, Oranuch Sanpool, Rutchanee Rodpai, Tongjit Thanchomnang, Wanida Kanarkard, Wanchai Maleewong, Ratthaphol Kraiklang, and Pewpan M Intapan. Current high prevalences of strongyloides stercoralis and opisthorchis viverrini infections in rural communities in northeast thailand and associated risk factors. BMC Public Health, 18:1-11, 2018.
- 73. ES Upatham, V Viyanant, WY Brockelman, S Kurathong, P Lee, and R Kraengraeng. Rate of reinfection by Opisthorchis viverrini in an endemic northeast Thai community after chemotherapy. International Journal for Parasitology, 18(5):643-649, 1988.
- 74. Chenghua Shen, Jae-hwan Kim, Jeong-Keun Lee, Young Mee Bae, Min-Ho Choi, Jin-Kyoung Oh, Min Kyung Lim, Hai-Rim Shin, and Sung-Tae Hong. Collection of Clonorchis sinensis adult worms from infected humans after praziquantel treatment. The Korean Journal of Parasitology. 45(2):149, 2007.
- 75 Thomas Brinkhoff. website, February 2024. URL http://www.citypopulation.de. City Population.